Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0020438 (
hypercalciuria
)
2,502
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The physiology of paracellular permeation of ions and solutes in the kidney is pivotally important but poorly understood. Claudins are the key components of the paracellular pathway. Defects in claudin function result in a broad range of renal diseases, including hypomagnesemia,
hypercalciuria
and nephrolithiasis. This review describes recent findings on the physiological function of claudins underlying paracellular transport mechanisms with a focus on renal Ca(2+) handling. We have uncovered a molecular mechanism underlying paracellular Ca(2+) transport in the thick ascending limb of Henle (TAL) that involves the functional interplay of three important claudin genes:
claudin-14
, -16 and -19, all of which are associated with human kidney diseases with
hypercalciuria
, nephrolithiasis and bone mineral loss. The Ca(2+) sensing receptor (CaSR) signaling in the kidney has long been a mystery. By analyzing small non-coding RNA molecules in the kidney, we have uncovered a novel microRNA based signaling pathway downstream of CaSR that directly regulates
claudin-14
gene expression and establishes the
claudin-14
molecule as a key regulator for renal Ca(2+) homeostasis. The molecular cascade of CaSR-microRNAs-claudins forms a regulatory loop to maintain proper Ca(2+) homeostasis in the kidney.
...
PMID:Lecture: New light on the role of claudins in the kidney. 2250 40
Kidney stones are a prevalent clinical condition imposing a large economic burden on the healthcare system.
Hypercalciuria
remains the major risk factor for development of a Ca(2+)-containing stone. The kidney's ability to alter Ca(2+) excretion in response to changes in serum Ca(2+) is in part mediated by the Ca(2+)-sensing receptor (CaSR). Recent studies revealed renal
claudin-14
(Cldn14) expression localized to the thick ascending limb (TAL) and its expression to be regulated via the CaSR. We find that Cldn14 expression is increased by high dietary Ca(2+) intake and by elevated serum Ca(2+) levels induced by prolonged 1,25-dihydroxyvitamin D3 administration. Consistent with this, activation of the CaSR in vivo via administration of the calcimimetic cinacalcet hydrochloride led to a 40-fold increase in Cldn14 mRNA. Moreover, overexpression of Cldn14 in two separate cell culture models decreased paracellular Ca(2+) flux by preferentially decreasing cation permeability, thereby increasing transepithelial resistance. These data support the existence of a mechanism whereby activation of the CaSR in the TAL increases Cldn14 expression, which in turn blocks the paracellular reabsorption of Ca(2+). This molecular mechanism likely facilitates renal Ca(2+) losses in response to elevated serum Ca(2+). Moreover, dysregulation of the newly described CaSR-Cldn14 axis likely contributes to the development of
hypercalciuria
and kidney stones.
...
PMID:Activation of the Ca(2+)-sensing receptor increases renal claudin-14 expression and urinary Ca(2+) excretion. 2328 89
Claudins are tight-junction membrane proteins that function as both pores and barriers in the paracellular pathway in epithelial cells. In the kidney, claudins determine the permeability and selectivity of different nephron segments along the renal tubule. In the proximal tubule, claudins have a role in the bulk reabsorption of salt and water. In the thick ascending limb, claudins are important for the reabsorption of calcium and magnesium and are tightly regulated by the calcium-sensing receptor. In the distal nephron, claudins need to form cation barriers and chloride pores to facilitate electrogenic sodium reabsorption and potassium and acid secretion. Aldosterone and the with-no-lysine (WNK) proteins likely regulate claudins to fine-tune distal nephron salt transport. Genetic mutations in claudin-16 and -19 cause familial hypomagnesemic
hypercalciuria
with nephrocalcinosis, whereas polymorphisms in
claudin-14
are associated with kidney stone risk. It is likely that additional roles for claudins in the pathogenesis of other types of kidney diseases have yet to be uncovered.
...
PMID:Claudins and the kidney. 2494 43
Familial hypomagnesaemia with
hypercalciuria
and nephrocalcinosis (FHHNC) is an autosomal-recessive renal tubular disorder characterized by excessive urinary losses of magnesium and calcium, bilateral nephrocalcinosis and progressive chronic renal failure. Presentation with FHHNC symptoms generally occurs early in childhood or before adolescence. At present, the only therapeutic option is supportive and consists of oral magnesium supplementation and thiazide diuretics. However, neither treatment seems to have a significant effect on the levels of serum magnesium or urine calcium or on the decline of renal function. In end-stage renal disease patients, renal transplantation is the only effective approach. This rare disease is caused by mutations in the CLDN16 or CLDN19 genes. Patients with mutations in CLDN19 also present severe ocular abnormalities such as myopia, nystagmus and macular colobamata. CLDN16 and CLDN19 encode the tight-junction proteins claudin-16 and claudin-19, respectively, which are expressed in the thick ascending limb of Henle's loop and form an essential complex for the paracellular reabsorption of magnesium and calcium. Claudin-19 is also expressed in retinal epithelium and peripheral neurons. Research studies using mouse and cell models have generated significant advances on the understanding of the pathophysiology of FHHNC. A recent finding has established that another member of the claudin family,
claudin-14
, plays a key regulatory role in paracellular cation reabsorption by inhibiting the claudin-16-claudin-19 complex. Furthermore, several studies on the molecular and cellular consequences of disease-causing CLDN16 and CLDN19 mutations have provided critical information for the development of potential therapeutic strategies.
...
PMID:Familial hypomagnesaemia with hypercalciuria and nephrocalcinosis: clinical and molecular characteristics. 2661 20
The greatest risk factor for kidney stones is
hypercalciuria
, the etiology of which is largely unknown. A recent genome-wide association study (GWAS) linked
hypercalciuria
and kidney stones to a
claudin-14
(
CLDN14
) risk haplotype. However, the underlying molecular mechanism was not delineated. Recently, renal
CLDN14
expression was found to increase in response to increased plasma calcium, thereby inducing calciuria. We hypothesized therefore that some children with
hypercalciuria
and kidney stones harbor a
CLDN14
variant that inappropriately increases gene expression. To test this hypothesis, we sequenced the
CLDN14
risk haplotype in a cohort of children with idiopathic
hypercalciuria
and kidney stones. An intronic SNP was more frequent in affected children. Dual luciferase and cell-based assays demonstrated increased reporter or
CLDN14
expression when this polymorphism was introduced. In silico studies predicted the SNP introduced a novel insulinoma-associated 1 (INSM1) transcription factor binding site. Consistent with this, repeating the dual luciferase assay in the presence of INSM1 further increased reporter expression. Our data suggest that children with the INSM1 binding site within the
CLDN14
risk haplotype have a higher likelihood of
hypercalciuria
and kidney stones. Enhanced
CLDN14
expression may play a role in the pathophysiology of their
hypercalciuria
.
...
PMID:A variant in a cis-regulatory element enhances claudin-14 expression and is associated with pediatric-onset hypercalciuria and kidney stones. 2822 5
Renal Ca
2+
reabsorption is essential for maintaining systemic Ca
2+
homeostasis and is tightly regulated through the parathyroid hormone (PTH)/PTHrP receptor (PTH1R) signaling pathway. We investigated the role of PTH1R in the kidney by generating a mouse model with targeted deletion of PTH1R in the thick ascending limb of Henle (TAL) and in distal convoluted tubules (DCTs):
Ksp-cre;Pth1r
fl/fl
Mutant mice exhibited
hypercalciuria
and had lower serum calcium and markedly increased serum PTH levels. Unexpectedly, proteins involved in transcellular Ca
2+
reabsorption in DCTs were not decreased. However, claudin14 (Cldn14), an inhibitory factor of the paracellular Ca
2+
transport in the TAL, was significantly increased. Analyses by flow cytometry as well as the use of
Cldn14-lacZ
knock-in reporter mice confirmed increased Cldn14 expression and promoter activity in the TAL of
Ksp-cre;Pth1r
fl/fl
mice. Moreover, PTH treatment of HEK293 cells stably transfected with
CLDN14
-GFP, together with PTH1R, induced cytosolic translocation of
CLDN14
from the tight junction. Furthermore, mice with high serum PTH levels, regardless of high or low serum calcium, demonstrated that PTH/PTH1R signaling exerts a suppressive effect on Cldn14. We therefore conclude that PTH1R signaling directly and indirectly regulates the paracellular Ca
2+
transport pathway by modulating Cldn14 expression in the TAL. Finally, systemic deletion of Cldn14 completely rescued the hypercalciuric and lower serum calcium phenotype in
Ksp-cre;Pth1r
fl/fl
mice, emphasizing the importance of PTH in inhibiting Cldn14. Consequently, suppressing
CLDN14
could provide a potential treatment to correct urinary Ca
2+
loss, particularly in patients with hypoparathyroidism.
...
PMID:Parathyroid hormone controls paracellular Ca
2+
transport in the thick ascending limb by regulating the tight-junction protein Claudin14. 2837 77
Claudins are integral proteins expressed at the tight junctions of epithelial and endothelial cells. In the mammalian kidney, every tubular segment express a specific set of claudins that give to that segment unique properties regarding permeability and selectivity of the paracellular pathway. So far, 3 claudins (10b, 16 and 19) have been causally traced to rare human syndromes: variants of
CLDN10b
cause HELIX syndrome and variants of
CLDN16
or
CLDN19
cause familial hypomagnesemia with
hypercalciuria
and nephrocalcinosis. The review summarizes our current knowledge on the physiology of mammalian tight junctions and paracellular ion transport, as well as on the role of the 3 above-mentioned claudins in health and disease. Claudin 14, although not having been causally linked to any rare renal disease, is also considered, because available evidence suggests that it may interact with claudin 16. Some single-nucleotide polymorphisms of
CLDN14
are associated with urinary calcium excretion and/or kidney stones. For each claudin considered, the pattern of expression, the function and the human syndrome caused by pathogenic variants are described.
...
PMID:Claudins in Renal Physiology and Pathology. 3216 58
Variations in the
CLDN14
gene have been linked to increased risk of
hypercalciuria
and kidney stone formation. However, the exact cellular localization of
CLDN14
and its regulation remain to be fully delineated. To this end, we generated a novel antibody that allowed the detection of
CLDN14
in paraffin-embedded renal sections. This showed
CLDN14
to be detectable in the kidney only after induction of hypercalcemia in rodent models. Protein expression in kidney is localized exclusively to the thick ascending limbs (TAL), mainly restricted to the cortical and upper medullary portion of the kidney. However not all cells in the TAL expressed the tight junction protein. In fact,
CLDN14
was primarily expressed in cells also expressing CLDN16, but devoid of CLDN10.
CLDN14
appeared in very superficial apical cell domains and near cell junctions in a belt-like formation along the apical cell periphery. In transgenic mice, Cldn14 promotor-driven LacZ activity did not show complete colocalization with
CLDN14
protein nor was it increased by hypercalcemia, suggesting that LacZ activity cannot be used as a marker for
CLDN14
localization and regulation in this model. In conclusion,
CLDN14
, showed a restricted localization pattern in the apical domain of select cells of the TAL.
...
PMID:Localization and Regulation of Claudin-14 in Experimental Models of Hypercalcemia. 3328 46